Arvinas (ARVN) Current Deferred Revenue (2017 - 2026)
Arvinas (ARVN) posted quarterly Current Deferred Revenue of $51.8 million for Q1 2026, down 80.03% year-over-year from $259.4 million in Q1 2025, and down 74.81% quarter-over-quarter from $205.6 million in Q4 2025.
Arvinas (ARVN) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Arvinas' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $51.8 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 80.03% year-over-year to $51.8 million; the TTM figure through Mar 2026 stood at $51.8 million (down 80.03% YoY), while the FY2025 annual figure was $205.6 million, down 54.13% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $51.8 million, down from $205.6 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $719.4 million in Q1 2022, with the low at $51.8 million in Q1 2026.
- The 5-year median for Current Deferred Revenue is $523.9 million (2024), against an average of $458.1 million.
- The sharpest annual moves came in 2022 and 2025: Current Deferred Revenue surged 1759.46% in 2022, then sank 82.83% in 2025.
- Arvinas' Current Deferred Revenue stood at $623.7 million in 2022, then declined by 11.94% to $549.2 million in 2023, then fell by 18.39% to $448.2 million in 2024, then plunged by 54.13% to $205.6 million in 2025, then sank by 74.81% to $51.8 million in 2026.
- Business Quant data shows ARVN's Current Deferred Revenue at $51.8 million in Q1 2026, $205.6 million in Q4 2025, and $215.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.80 Mn |
| Dec 31, 2025 | 205.60 Mn |
| Sep 30, 2025 | 215.10 Mn |
| Jun 30, 2025 | 102.90 Mn |
| Mar 31, 2025 | 259.40 Mn |
| Dec 31, 2024 | 448.20 Mn |
| Sep 30, 2024 | 503.70 Mn |
| Jun 30, 2024 | 599.20 Mn |
| Mar 31, 2024 | 523.90 Mn |
| Dec 31, 2023 | 549.20 Mn |
| Sep 30, 2023 | 506.10 Mn |
| Jun 30, 2023 | 540.60 Mn |
| Mar 31, 2023 | 593.80 Mn |
| Dec 31, 2022 | 623.70 Mn |
| Sep 30, 2022 | 657.70 Mn |
| Jun 30, 2022 | 688.00 Mn |
| Mar 31, 2022 | 719.40 Mn |
| Dec 31, 2021 | 740.50 Mn |
| Sep 30, 2021 | 763.40 Mn |
| Jun 30, 2021 | 37.00 Mn |